BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35899387)

  • 1. Analysis of rare driving events in pediatric acute myeloid leukemia.
    Noort S; Oosterwijk JV; Ma J; Garfinkle EAR; Nance S; Walsh M; Song G; Reinhardt D; Pigazzi M; Locatelli F; Hasle H; Abrahamsson J; Jarosova M; Kelaidi C; Polychronopoulou S; Van den Heuvel-Eibrink MM; Fornerod M; Gruber TA; Zwaan CM
    Haematologica; 2023 Jan; 108(1):48-60. PubMed ID: 35899387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia.
    Shiba N; Yoshida K; Hara Y; Yamato G; Shiraishi Y; Matsuo H; Okuno Y; Chiba K; Tanaka H; Kaburagi T; Takeuchi M; Ohki K; Sanada M; Okubo J; Tomizawa D; Taki T; Shimada A; Sotomatsu M; Horibe K; Taga T; Adachi S; Tawa A; Miyano S; Ogawa S; Hayashi Y
    Blood Adv; 2019 Oct; 3(20):3157-3169. PubMed ID: 31648321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients.
    De Clara E; Gourvest M; Ma H; Vergez F; Tosolini M; Dejean S; Demur C; Delabesse E; Recher C; Touriol C; Martelli MP; Falini B; Brousset P; Bousquet M
    Haematologica; 2017 Oct; 102(10):1718-1726. PubMed ID: 28679652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group.
    Noort S; Zimmermann M; Reinhardt D; Cuccuini W; Pigazzi M; Smith J; Ries RE; Alonzo TA; Hirsch B; Tomizawa D; Locatelli F; Gruber TA; Raimondi S; Sonneveld E; Cheuk DK; Dworzak M; Stary J; Abrahamsson J; Arad-Cohen N; Czogala M; De Moerloose B; Hasle H; Meshinchi S; van den Heuvel-Eibrink M; Zwaan CM
    Blood; 2018 Oct; 132(15):1584-1592. PubMed ID: 30150206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous detection of mutations and copy number variation of NPM1 in the acute myeloid leukemia using multiplex ligation-dependent probe amplification.
    Marcinkowska-Swojak M; Handschuh L; Wojciechowski P; Goralski M; Tomaszewski K; Kazmierczak M; Lewandowski K; Komarnicki M; Blazewicz J; Figlerowicz M; Kozlowski P
    Mutat Res; 2016 Apr; 786():14-26. PubMed ID: 26894557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
    Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
    Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.
    Hollink IH; van den Heuvel-Eibrink MM; Arentsen-Peters ST; Zimmermann M; Peeters JK; Valk PJ; Balgobind BV; Sonneveld E; Kaspers GJ; de Bont ES; Trka J; Baruchel A; Creutzig U; Pieters R; Reinhardt D; Zwaan CM
    Haematologica; 2011 Mar; 96(3):384-92. PubMed ID: 21134981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis.
    Konoplev S; Huang X; Drabkin HA; Koeppen H; Jones D; Kantarjian HM; Garcia-Manero G; Chen W; Medeiros LJ; Bueso-Ramos CE
    Cancer; 2009 Oct; 115(20):4737-44. PubMed ID: 19637342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Impact of Concurrent DNMT3A, FLT3 and NPM1 Gene Mutations in Acute Myeloid Leukemia Patients.
    Elrhman HAEA; El-Meligui YM; Elalawi SM
    Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e960-e969. PubMed ID: 34376373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
    Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
    J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia.
    Russ AC; Sander S; Lück SC; Lang KM; Bauer M; Rücker FG; Kestler HA; Schlenk RF; Döhner H; Holzmann K; Döhner K; Bullinger L
    Haematologica; 2011 Dec; 96(12):1783-91. PubMed ID: 21880628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Curious Novel Combination of
    Venanzi A; Rossi R; Martino G; Annibali O; Avvisati G; Mameli MG; Sportoletti P; Tiacci E; Falini B; Martelli MP
    Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573408
    [No Abstract]   [Full Text] [Related]  

  • 13. NPM1-mutated acute myeloid leukemia: from bench to bedside.
    Falini B; Brunetti L; Sportoletti P; Martelli MP
    Blood; 2020 Oct; 136(15):1707-1721. PubMed ID: 32609823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?
    Falini B; Martelli MP; Bolli N; Sportoletti P; Liso A; Tiacci E; Haferlach T
    Blood; 2011 Jan; 117(4):1109-20. PubMed ID: 21030560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemia.
    Konoplev S; Lin P; Yin CC; Lin E; Nogueras González GM; Kantarjian HM; Andreeff M; Medeiros LJ; Konopleva M
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):686-92. PubMed ID: 24035716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Association of Next Generation Sequencing Based Genotypic Profiling with MICM Characteristics in NPM1 Mutated Acute Myeloid Leukemia].
    Wang B; Ling Y; Dai L; Gu WY; Zhang XW; Xing SS; Li HQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):56-60. PubMed ID: 35123604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical Significance of Low Expression of LncRNA CASC15 in Acute Myeloid Leukemia with NPM1 Mutations].
    Xia PH; Xu ZJ; Jin Y; Ma JC; Wen XM; Yuan Q; Leng JY; Qian J; Lin J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):659-670. PubMed ID: 35680788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant NPM1-regulated lncRNA HOTAIRM1 promotes leukemia cell autophagy and proliferation by targeting EGR1 and ULK3.
    Jing Y; Jiang X; Lei L; Peng M; Ren J; Xiao Q; Tao Y; Tao Y; Huang J; Wang L; Tang Y; Yang Z; Yang Z; Zhang L
    J Exp Clin Cancer Res; 2021 Oct; 40(1):312. PubMed ID: 34615546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational spectrum of
    Pettersson L; Holmgren B; Juliusson G; Lazarevic VL; Ehinger M
    Leuk Lymphoma; 2021 Aug; 62(8):1958-1966. PubMed ID: 33711909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel mutations of the nucleophosmin (NPM-1) gene in Egyptian patients with acute myeloid leukemia: a pilot study.
    Kassem N; Hamid AA; Attia T; Baathallah S; Mahmoud S; Moemen E; Safwat E; Khalaf M; Shaker O
    J Egypt Natl Canc Inst; 2011 Jun; 23(2):73-8. PubMed ID: 22099964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.